| Factor |
No. |
Only H (n=44) (n=65) |
Multiple (n=33) (n=239) |
P value |
| Sex |
|
|
|
0.143 |
| Male |
66 |
40 (90.9%) |
26 (78.9%) |
|
| Female |
11 |
4 (9.1%) |
7 (21.2%) |
|
| Age /years old |
|
|
|
0.35 |
| ≥60 |
63 |
38 (86.4%) |
25 (78.1%) |
|
| < 60 |
13 |
6 (13.6%) |
7 (21.8%) |
|
| Macroscopic type |
|
|
|
0.066 |
| Type 0 |
1 |
1 (2.3%) |
0 |
|
| 1, 2 |
31 |
22 (50.0%) |
9 (29.0%) |
|
| 3, 4 |
37 |
18 (40.9%) |
19 (61.3%) |
|
| 5 |
6 |
3 (6.8%) |
3 (9.7%) |
|
| Site |
|
|
|
0.863 |
| L (lower) |
32 |
19 (43.2%) |
13 (40.6%) |
|
| M (middle) |
20 |
10 (22.7%) |
10 (31.3%) |
|
| U (upper) |
24 |
15 (34.1%) |
9 (28.1%) |
|
| The number of sites |
|
|
|
0.357 |
| 1 |
23 |
14 (31.8%) |
9 (28.1%) |
|
| 2 |
28 |
18 (40.9%) |
10 (31.3%) |
|
| ≥3 |
25 |
12 (27.3%) |
13 (40.6%) |
|
| Depth |
|
|
|
0.692 |
| T1, T2, T3 |
4 |
4 (10.0%) |
0 |
|
| T4a |
51 |
27 (67.5%) |
24 (82.8%) |
|
| T4b |
14 |
9 (22.5%) |
5 (17.2%) |
|
| Histology |
|
|
|
0.239 |
| differentiated |
33 |
24 (66.7%) |
9 (50.0%) |
|
| undifferentiated |
21 |
12 (33.3%) |
9 (50.0%) |
|
| Stromal pattern |
|
|
|
0.111 |
| medullary |
31 |
23 (63.9%) |
8 (44.4%) |
|
| intermediate |
22 |
13 (36.1%) |
9 (50.0%) |
|
| scirrhous |
1 |
0 |
1 (5.6%) |
|
| INF |
|
|
|
0.006* |
| a |
20 |
17 (47.2%) |
3 (16.7%) |
|
| b |
26 |
17 (47.2%) |
9 (50.0%) |
|
| c |
8 |
2 (5.6%) |
6 (33.3%) |
|
| ly |
|
|
|
0.015* |
| 0 |
1 |
1 (2.8%) |
0 |
|
| 1,2 |
19 |
17 (47.2%) |
2 (11.8%) |
|
| 3 |
33 |
18 (50.0%) |
15 (88.2%) |
|
| v |
|
|
|
0.153 |
| 0,1 |
13 |
11 (30.6%) |
2 (11.8%) |
|
| 2,3 |
40 |
25 (69.4%) |
15 (88.2%) |
|
| Lymph node metastasis |
|
|
|
0.011* |
| 0 |
6 |
6 (17.1%) |
0 |
|
| 1,2 |
15 |
14 (40.0%) |
1 (6.3%) |
|
| 3 |
30 |
15 (42.9%) |
15 (93.8%) |
|
| Gastrectomy |
|
|
|
0.012* |
| (-) |
23 |
8 (18.2%) |
15 (45.5%) |
|
| (+) |
54 |
36 (81.8%) |
18 (54.5%) |
|
| Chemotherapy |
|
|
|
0.144 |
| (-) |
29 |
13 (31.7%) |
16 (48.5%) |
|
| (+) |
45 |
28 (68.3%) |
17 (51.5%) |
|
| New anti-cancer drug |
|
|
|
0.9 |
| (-) |
18 |
11 (39.3%) |
7 (41.2%) |
|
| (+) |
27 |
17 (60.7%) |
10 (58.8%) |
|
| Lymph node dissection |
|
|
|
0.016* |
| D0,D1 |
32 |
17 (47.2%) |
15 (83.3%) |
|
| ≥ D2 |
22 |
19 (52.8%) |
3 (16.7%) |
|
| Tumor size |
|
|
|
0.146 |
| < 100mm |
39 |
28 (80.0%) |
11 (61.1%) |
|
| ≥ 100mm |
14 |
7 (20.0%) |
7 (38.9%) |
|
| Residual tumor |
|
|
|
0.8 |
| R0 |
2 |
2 (5.6%) |
0 |
|
| R2 |
52 |
34 (94.4%) |
18 (100%) |
|
| The number of metastatic nodule |
|
|
|
0.268 |
| solitary |
11 |
8 (18.2%) |
3 (9.1%) |
|
| multiple |
66 |
36 (81.8%) |
30 (90.9%) |
|
| The number of metastatic nodule |
|
|
|
0.007* |
| ≤ 3 |
25 |
20 (45.5%) |
5 (15.2%) |
|
| ≥ 4 |
52 |
24 (54.5%) |
28 (84.8%) |
|
| Hepatectomy |
|
|
|
0.744 |
| (-) |
71 |
38 (86.4%) |
33 (100%) |
|
| (+) |
6 |
6 (13.6%) |
0 |
|
| HAI |
|
|
|
0.025* |
| (-) |
60 |
30 (68.2%) |
30 (90.9%) |
|
| (+) |
17 |
14 (31.8%) |
3 (9.1%) |
|
| Systemic chemotherapy |
|
|
|
0.304 |
| (-) |
31 |
15 (36.6%) |
16 (48.5%) |
|
| (+) |
43 |
26 (63.4%) |
17 (51.5%) |
|
*P<0.05 indicates statistical significance. |
